Case study: Technology initiative led to advanced lead optimization screening processes at Bristol-Myers Squibb, 2004-2009

Drug Discovery Today

Volumn 17, Issue 13-14, 2012, Pages 733-740

  Zhang, Litao ^a   Cvijic, Mary Ellen ^a   Lippy, Jonathan ^a   Myslik, James ^a   Brenner, Stephen L ^a   Binnie, Alastair ^a   Houston, John G ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED LEAD OPTIMIZATION SCREENING PROCESS; CASE STUDY; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG SCREENING; REVIEW; TECHNOLOGY;

ANIMALS; DRUG DISCOVERY; DRUG INDUSTRY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EFFICIENCY, ORGANIZATIONAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INVESTMENTS; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 84863515057     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.02.012     Document Type: Review

References (29)

1. J.G. Houston Technologies for improving lead optimization Int. Drug Discov. 2006 Available at: http://www.internationaldrugdiscovery.com/ ViewArticle.aspx?ContentID=35
2. S. Fox High-throughput screening: update on practices and success J. Biomol. Screen. 11 2006 864 869 (Pubitemid 44562328)
3. D.A. Pereira, and J.A. Williams Origin and evolution of high throughput screening Br. J. Pharmacol. 152 2007 53 61 (Pubitemid 47339909)
4. L.M. Mayr, and D. Bojanic Novel trends in high-throughput screening Curr. Opin. Pharmacol. 9 2009 580 588
5. J.P. Valentin, and T. Hammond Safety and secondary pharmacology: successes, threats, challenges and opportunities J. Pharmacol. Toxicol. Methods 58 2008 77 87
6. A. Whitty, and M.H. Gelb Critical challenges and emerging paradigms in drug discovery Curr. Opin. Chem. Biol. 14 2010 437 439
7. J.A. Frearson, and I.T. Collie HTS and hit finding in academia - from chemical genomics to drug discovery Drug Discov. Today 14 2009 1150 1158
8. D.H. Drewry, and R. Macarron Enhancements of screening collections to address areas of unmet medical need: an industry perspective Curr. Opin. Chem. Biol. 14 2010 289 298
9. J. Arrowsmith Trial watch: Phase II failures: 2008-2010 Nat. Rev. Drug Discov. 10 2011 328 329
10. J. Arrowsmith Trial watch: Phase III and submission failures: 2007-2010 Nat. Rev. Drug Discov. 10 2011 87
11. Y. Yang Target discovery from data mining approaches Drug Discov. Today 14 2009 147 154
12. J.G. Houston HTS: productivity or oblivion? J. Biomol. Screen. 4 1999 229 230
13. J.G. Houston Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006 Drug Discov. Today 13 2008 44 51
14. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 8 2004 711 715 (Pubitemid 39173511)
15. B. Faller High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis Expert. Opin. Drug Metab. Toxicol. 2 6 2006 823 833 (Pubitemid 44911534)
16. S.L. Matson Best practices in compound management for preserving compound integrity and accurately providing samples for assays J. Biomol. Screen. 14 2009 476 484
17. C.W. Johnson Efficient and effective compound management to support lead optimization J. Biomol. Screen. 14 2009 523 530
18. V. Schnecke, and J. Bostrom Computational chemistry-driven decision making in lead generation Drug Discov. Today 11 2006 43 50 (Pubitemid 43227851)
19. T.W. Cooper Factors determining the selection of organic reactions by medicinal chemists and the use of these reactions in arrays (small focused libraries) Angew. Chem. Int. Ed. Engl. 49 2010 8082 8091
20. P.L. Myers Will combinatorial chemistry deliver real medicines? Curr. Opin. Biotechnol. 8 1997 701 707 (Pubitemid 27517246)
21. M. Colombo, and I. Peretto Chemistry strategies in early drug discovery: an overview of recent trends Drug Discov. Today 13 2008 677 684
22. D. Hunter Life in the fast lane: high-throughput chemistry for lead generation and optimisation J. Cell. Biochem. 37 Suppl. 2001 22 27 (Pubitemid 34135902)
23. M.L. George Lean Six Sigma: Combining Six Sigma with Lean Sigma 2002 McGraw-Hill
24. M.L. George, and D. Rowlands What is Lean Sigma? 2004 McGraw-Hill
25. J. Chen Application of large-scale transient transfection to cell-based functional assays for ion channels and GPCRs Methods Enzymol. 485 2010 293 309
26. G.J. Zaman Cryopreserved cells facilitate cell-based drug discovery Drug Discov. Today 12 2007 521 526 (Pubitemid 47039304)
27. A. Sewing Evolution in thinking and processes? Drug Discov. Today: Technol. 5 2008 e9 e14
28. E.H. Kerns, and L. Di Pharmaceutical profiling in drug discovery Drug Discov. Today 8 2003 316 323 (Pubitemid 36332223)
29. J.G. Houston The impact of automation on high-throughput screening Methods Find. Exp. Clin. Pharmacol. 19 Suppl. A 1997 43 45 (Pubitemid 27505033)